Latent Tuberculosis Clinical Trials

9 recruiting

Latent Tuberculosis Trials at a Glance

11 actively recruiting trials for latent tuberculosis are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Liupanshui, Zunyi, and Dalian. Lead sponsors running latent tuberculosis studies include Huashan Hospital, Region Skane, and Centers for Disease Control and Prevention.

Browse latent tuberculosis trials by phase

Treatments under study

About Latent Tuberculosis Clinical Trials

Looking for clinical trials for Latent Tuberculosis? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Latent Tuberculosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Latent Tuberculosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

Training Protocol on the Natural History of Tuberculosis

TuberculosisLatent TuberculosisMycobacterium Infections+2 more
National Institute of Allergy and Infectious Diseases (NIAID)150 enrolled1 locationNCT01212003
Recruiting
Phase 3

TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts

TuberculosisLatent Tuberculosis
Huashan Hospital3,520 enrolled47 locationsNCT06022146
Recruiting
Not Applicable

Economic Incentives and vDOT for Latent Tuberculosis Infection

Latent Tuberculosis
Johns Hopkins University399 enrolled1 locationNCT05022862
Recruiting
Phase 3

Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Latent Tuberculosis Infection
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.780 enrolled8 locationsNCT05899179
Recruiting

Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients

Latent Tuberculosis InfectionTuberculosis
Huashan Hospital31,440 enrolled44 locationsNCT06033807
Recruiting

Lung Innate Immunity and Microbiome After Tuberculosis Exposure

TuberculosisLatent Tuberculosis
University of Oxford50 enrolled3 locationsNCT06526689
Recruiting
Phase 1

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

Pediatric HIV InfectionLatent Tuberculosis
Brigham and Women's Hospital25 enrolled1 locationNCT06281834
Recruiting
Phase 2Phase 3

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

Latent Tuberculosis
Centers for Disease Control and Prevention3,400 enrolled16 locationsNCT03474029
Recruiting

Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis

Staphylococcus AureusLatent Tuberculosis
Region Skane100 enrolled1 locationNCT05073926
Recruiting

New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis

Latent TuberculosisMycobacterium TuberculosisPersistent Infection
Region Skane130 enrolled1 locationNCT05621343
Recruiting

Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students

TuberculosisTuberculosis, PulmonaryTuberculosis Infection+2 more
Eleonora Nucera2,040 enrolled1 locationNCT05756582